Tumour-intrinsic resistance to immune checkpoint blockade (original) (raw)

• Chowell, D. et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 359, 582–587 (2018).
  Article CAS PubMed Google Scholar
• Pitt, J. M. et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity 44, 1255–1269 (2016).
  Article CAS PubMed Google Scholar
• Fessler, J., Matson, V. & Gajewski, T. F. Exploring the emerging role of the microbiome in cancer immunotherapy. J. Immunother. Cancer 7, 108 (2019).
  Article PubMed PubMed Central Google Scholar
• Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500–2501 (2017).
  Article PubMed PubMed Central Google Scholar
• Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015). Association of mutational burden and sensitivity to immune checkpoint blockade has been observed across malignancies, including lung cancer. This study provides further support for the importance of tumour-intrinsic biology for sensitivity to immune checkpoint blockade.
  Article CAS PubMed PubMed Central Google Scholar
• Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• van Rooij, N. et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31, e439–e442 (2013).
  Article PubMed Google Scholar
• Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577–581 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641–645 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217–221 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Dighe, A. S., Richards, E., Old, L. J. & Schreiber, R. D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1, 447–456 (1994).
  Article CAS PubMed Google Scholar
• Kaplan, D. H. et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl Acad. Sci. USA 95, 7556–7561 (1998). Dighe et al. (1994) and Kaplan et al. (1998) provide early data indicating the importance of tumour sensitivity to IFNγ in the rejection of tumours by the immune system.
  Article CAS PubMed PubMed Central Google Scholar
• Manguso, R. T. et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547, 413–418 (2017). This study uses an in vivo CRISPR screen of the B16 mouse melanoma model treated with anti-PD1 and GVAX.
  Article CAS PubMed PubMed Central Google Scholar
• Patel, S. J. et al. Identification of essential genes for cancer immunotherapy. Nature 548, 537–542 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Pan, D. et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science 359, 770–775 (2018). Manguso et al. (2017), Patel et al. (2017) and Pan et al. (2018) describe important CRISPR screens that identify tumour-intrinsic mechanisms of resistance to immunotherapy using in vitro co-culture of B16 mouse melanoma cells and tumour-specific T cells.
  Article CAS PubMed PubMed Central Google Scholar
• Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819–829 (2016). This study provides clinical data demonstrating the role of mutations in the interferon signalling pathway ( JAK1 and JAK 2) and antigen presentation ( B2M ) in acquired resistance to immune checkpoint blockade.
  Article CAS PubMed PubMed Central Google Scholar
• Gao, J. et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167, 397–404 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Sucker, A. et al. Acquired IFNgamma resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. Nature communications 8, 15440 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Wilson, E. B. et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340, 202–207 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Teijaro, J. R. et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340, 207–211 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Benci, J. L. et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167, 1540–1554.e12 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Kirkwood, J. M. et al. Effect of JAK/STAT or PI3Kδ plus PD-1 inhibition on the tumor microenvironment: Biomarker results from a phase Ib study in patients with advanced solid tumors. Cancer Res. 78 (Suppl.), CT176 (2018).
  Google Scholar
• Bach, E. A., Aguet, M. & Schreiber, R. D. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu. Rev. Immunol. 15, 563–591 (1997).
  Article CAS PubMed Google Scholar
• Paucker, K., Cantell, K. & Henle, W. Quantitative studies on viral interference in suspended L cells. III. Effect of interfering viruses and interferon on the growth rate of cells. Virology 17, 324–334 (1962).
  Article CAS PubMed Google Scholar
• Basham, T. Y. & Merigan, T. C. Recombinant interferon-gamma increases HLA-DR synthesis and expression. J. Immunol. 130, 1492–1494 (1983).
  CAS PubMed Google Scholar
• King, D. P. & Jones, P. P. Induction of Ia and H-2 antigens on a macrophage cell line by immune interferon. J. Immunol. 131, 315–318 (1983).
  CAS PubMed Google Scholar
• Cole, K. E. et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J. Exp. Med. 187, 2009–2021 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Farber, J. M. A macrophage mRNA selectively induced by gamma-interferon encodes a member of the platelet factor 4 family of cytokines. Proc. Natl Acad. Sci. USA 87, 5238–5242 (1990).
  Article CAS PubMed PubMed Central Google Scholar
• Luster, A. D., Unkeless, J. C. & Ravetch, J. V. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 315, 672–676 (1985).
  Article CAS PubMed Google Scholar
• Rodig, S. J. et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci. Transl. Med. 10, (2018).
  Article PubMed CAS Google Scholar
• Johnson, D. B. et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat. Commun. 7, 10582 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Johnson, D. B. et al. Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. JCI Insight. 3, (2018).
• Shankaran, V. et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107–1111 (2001).
  Article CAS PubMed Google Scholar
• Restifo, N. P. et al. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177, 265–272 (1993). The first report of mutations in antigen processing machinery as a mechanism of resistance to immunotherapy in cancer patients.
  Article CAS PubMed Google Scholar
• D’Urso, C. M. et al. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J. Clin. Invest. 87, 284–292 (1991).
  Article CAS PubMed PubMed Central Google Scholar
• Restifo, N. P. et al. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl. Cancer Inst. 88, 100–108 (1996).
  Article CAS PubMed Google Scholar
• Sucker, A. et al. Genetic evolution of T-cell resistance in the course of melanoma progression. Clin. Cancer Res. 20, 6593–6604 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171, 1259–1271.e11 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Grasso, C. S. et al. Genetic mechanisms of immune evasion in colorectal cancer. Cancer Discov. 8, 730–749 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Sade-Feldman, M. et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 8, 1136 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Huang, L. et al. The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression. Clin. Cancer Res. 2483, 2017 (2018).
  Google Scholar
• Wellenstein, M. D. & de Visser, K. E. Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape. Immunity 48, 399–416 (2018).
  Article CAS PubMed Google Scholar
• Spranger, S. & Gajewski, T. F. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat. Rev. Cancer 18, 139–147 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Yaguchi, T. et al. Immune suppression and resistance mediated by constitutive activation of Wnt/beta-catenin signaling in human melanoma cells. J. Immunol. 189, 2110–2117 (2012).
  Article CAS PubMed Google Scholar
• Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523, 231–235 (2015). A key article on the role of tumour-intrinsic WNT signalling in immune evasion of cancer.
  Article CAS PubMed Google Scholar
• Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector t cell trafficking and adoptive t cell therapy. Cancer Cell 31, 711–723.e714 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Holtzhausen, A. et al. Melanoma-derived Wnt5a promotes local dendritic-cell expression of IDO and immunotolerance: opportunities for pharmacologic enhancement of immunotherapy. Cancer Immunol. Res. 3, 1082–1095 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Zhao, F. et al. Paracrine Wnt5a-beta-catenin signaling triggers a metabolic program that drives dendritic cell tolerization. Immunity 48, 147–160.e7 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Jimenez-Sanchez, A. et al. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell 170, 927–938.e20 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Sridharan, V. et al. Immune profiling of adenoid cystic carcinoma: PD-L2 expression and associations with tumor-infiltrating lymphocytes. Cancer Immunol. Res. 4, 679–687 (2016).
  Article CAS PubMed Google Scholar
• Seiwert, T. Y. et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin. Cancer Res. 21, 632–641 (2015).
  Article CAS PubMed Google Scholar
• Sweis, R. F. et al. Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer. Cancer Immunol. Res. 4, 563–568 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Abril-Rodriguez, G. T. et al. PAK4 inhibition reverses immune cell exclusion and overcomes resistance to checkpoint blockade therapy [abstract O39]. SITC https://sitc.sitcancer.org/2018/abstracts/titles/?category=Mechanisms+of+Resistance+to+Immunotherapy (2018).
• Hunter, T. & Pines, J. Cyclins and cancer. Cell 66, 1071–1074 (1991).
  Article CAS PubMed Google Scholar
• Schaer, D. A. et al. The CDK4/6 inhibitor abemaciclib induces a t cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade. Cell Rep. 22, 2978–2994 (2018).
  Article CAS PubMed Google Scholar
• Goel, S. et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature 548, 471–475 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Jerby-Arnon, L. et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell 175, 984–997.e24 (2018). In this study, single-cell transcriptomic analysis identifies a CDK4/CDK6-driven signature associated with immune exclusion and poor response to immune checkpoint blockade.
  Article CAS PubMed PubMed Central Google Scholar
• Deng, J. et al. CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 8, 216–233 (2018).
  Article CAS PubMed Google Scholar
• Sumimoto, H., Imabayashi, F., Iwata, T. & Kawakami, Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med. 203, 1651–1656 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Boni, A. et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70, 5213–5219 (2010).
  Article CAS PubMed Google Scholar
• Frederick, D. T. et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 19, 1225–1231 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Sapkota, B., Hill, C. E. & Pollack, B. P. Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells. Oncoimmunology 2, e22890 (2013).
  Article PubMed PubMed Central Google Scholar
• Acquavella, N. et al. Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest. Cancer Immunol. Res. 3, 37–47 (2015).
  Article CAS PubMed Google Scholar
• Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35–44 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934–949.e16 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Ebert, P. J. R. et al. MAP kinase inhibition promotes t cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity 44, 609–621 (2016).
  Article CAS PubMed Google Scholar
• Hu-Lieskovan, S. et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci. Transl. Med. 7, 279ra241 (2015).
  Article CAS Google Scholar
• Ribas, A. et al. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat. Med. 25, 936–940 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Ascierto, P. A. et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat. Med. 25, 941–946 (2019).
  Article CAS PubMed Google Scholar
• Sullivan, R. J. et al. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat. Med. 25, 929–935 (2019).
  Article CAS PubMed Google Scholar
• Steck, P. A. et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15, 356–362 (1997).
  Article CAS PubMed Google Scholar
• Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943–1947 (1997).
  Article CAS PubMed Google Scholar
• Peng, W. et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 6, 202–216 (2016).
  Article CAS PubMed Google Scholar
• George, S. et al. Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. Immunity 46, 197–204 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Li, S. et al. The tumor suppressor PTEN has a critical role in antiviral innate immunity. Nat. Immunol. 17, 241–249 (2016).
  Article CAS PubMed Google Scholar
• Sai, J. et al. PI3K inhibition reduces mammary tumor growth and facilitates antitumor immunity and anti-PD1 responses. Clin. Cancer Res. 23, 3371–3384 (2017).
  Article CAS PubMed Google Scholar
• Ali, K. et al. Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 510, 407–411 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Kaneda, M. M. et al. PI3Kgamma is a molecular switch that controls immune suppression. Nature 539, 437–442 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Mehta, A. et al. Immunotherapy resistance by inflammation-induced dedifferentiation. Cancer Discov. 8, 935–943 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Miao, Y. et al. Adaptive immune resistance emerges from tumor-initiating stem cells. Cell 177, 1172–1186.e14 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Castagnoli, L. et al. WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer. Oncogene 38, 4047–4060 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Paczulla, A. M. et al. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature 572, 254–259 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Zhan, T., Rindtorff, N. & Boutros, M. Wnt signaling in cancer. Oncogene 36, 1461–1473 (2017).
  Article CAS PubMed Google Scholar
• Menshawy, A. et al. Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials. Melanoma Res. 28, 371–379 (2018).
  CAS PubMed Google Scholar
• Dudley, M. E. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850–854 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Zeng, D. Q. et al. Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer. Oncotarget 7, 13765–13781 (2016).
  PubMed PubMed Central Google Scholar
• Thomas, N. E. et al. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J. Clin. Oncol. 31, 4252–4259 (2013).
  Article PubMed PubMed Central Google Scholar
• Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006).
  Article CAS PubMed Google Scholar
• Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203–213 (2003).
  Article CAS PubMed Google Scholar
• Chen, P. L. et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 6, 827–837 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014). This study shows that CD8 + T cell density at the invasive margin is predictive of response to anti-PD1 immune checkpoint blockade in patients with melanoma. The presence of tumour-infiltrating T cells is likely to be a biomarker of pre-existing antitumour immune responses in patients who respond to anti-PD1 therapy.
  Article CAS PubMed PubMed Central Google Scholar
• Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015). This article suggests that the observation of high response rates to anti-PD1 therapy for tumours with high mutational burden due to mismatch repair deficiency highlights how tumour biology can dictate the response to immune checkpoint blockade.
  Article CAS PubMed PubMed Central Google Scholar
• Mariathasan, S. et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544–548 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251–1259 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018–2028 (2015).
  Article PubMed Google Scholar
• Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122–133 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330 (2015).
  Article CAS PubMed Google Scholar
• Forde, P. M. et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N. Engl. J. Med. 378, 1976–1986 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Garcia-Diaz, A. et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 19, 1189–1201 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Platanias, L. C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5, 375–386 (2005).
  Article CAS PubMed Google Scholar
• Chen, G. et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560, 382–386 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Shin, D. S. et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 7, 188–201 (2017).
  Article CAS PubMed Google Scholar
• Ribas, A. & Hu-Lieskovan, S. What does PD-L1 positive or negative mean? J. Exp. Med. 213, 2835–2840 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Sun, C., Mezzadra, R. & Schumacher, T. N. Regulation and function of the PD-L1 checkpoint. Immunity 48, 434–452 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453–457 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Becht, E. et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 17, 218 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Aran, D., Hu, Z. & Butte, A. J. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 18, 220 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170, 1109–1119.e10 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Ayers, M. et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930–2940 (2017).
  Article PubMed PubMed Central Google Scholar
• Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48–61 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Chiappinelli, K. B. et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162, 974–986 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998–1013.e20 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Nishino, M., Ramaiya, N. H., Hatabu, H. & Hodi, F. S. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat. Rev. Clin. Oncol. 14, 655–668 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463–1469 (2016). Using whole-exome sequencing from separate quadrants of a single tumour, McGranahan et al. highlight that clonal neoantigens, rather than subclonal neoantigens, are most closely associated with response to immune checkpoint blockade.
  Article CAS PubMed PubMed Central Google Scholar
• The problem with neoantigen prediction. Nat. Biotechnol. 35, 97, (2017).
• Vitiello, A. & Zanetti, M. Neoantigen prediction and the need for validation. Nat. Biotechnol. 35, 815–817 (2017).
  Article CAS PubMed Google Scholar
• Nathanson, T. et al. Somatic mutations and neoepitope homology in melanomas treated with CTLA-4 blockade. Cancer Immunol. Res. 5, 84–91 (2017).
  Article CAS PubMed Google Scholar
• Spranger, S. et al. Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc. Natl Acad. Sci. USA. 113, E7759–E7768 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, (2018). This article shows that tumour mutational burden and pre-existing immune infiltrates provide distinct and complementary pieces of information on potential response to anti-PD1 immune checkpoint blockade.
• Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069–1086 (2018).
  Article PubMed Google Scholar
• Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Gardner, A. & Ruffell, B. Dendritic cells and cancer immunity. Trends Immunol. 37, 855–865 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Redelman-Sidi, G., Glickman, M. S. & Bochner, B. H. The mechanism of action of BCG therapy for bladder cancer–a current perspective. Nat. Rev. Urol. 11, 153–162 (2014).
  Article CAS PubMed Google Scholar
• Kalbasi, A., June, C. H., Haas, N. & Vapiwala, N. Radiation and immunotherapy: a synergistic combination. J. Clin. Invest. 123, 2756–2763 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Schaue, D. & McBride, W. H. Opportunities and challenges of radiotherapy for treating cancer. Nat. Rev. Clin. Oncol. 12, 527–540 (2015).
  Article PubMed PubMed Central Google Scholar
• Weichselbaum, R. R., Liang, H., Deng, L. & Fu, Y. X. Radiotherapy and immunotherapy: a beneficial liaison? Nat. Rev. Clin. Oncol. 14, 365–379 (2017).
  Article CAS PubMed Google Scholar
• Demaria, S., Coleman, C. N. & Formenti, S. C. Radiotherapy: changing the game in immunotherapy. Trends cancer 2, 286–294 (2016).
  Article PubMed PubMed Central Google Scholar
• Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51–72 (2013).
  Article CAS PubMed Google Scholar
• Deng, L. et al. STING-Dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41, 843–852 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Apetoh, L. et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050–1059 (2007).
  Article CAS PubMed Google Scholar
• Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373–377 (2015).
  Article CAS PubMed Google Scholar
• Seifert, L. et al. Radiation therapy induces macrophages to suppress t-cell responses against pancreatic tumors in mice. Gastroenterology 150, 1659–1672.e1655 (2016).
  Article PubMed Google Scholar
• Patel, S. A. & Minn, A. J. Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies. Immunity 48, 417–433 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Goldsmith, K., Chen, W., Johnson, D. C. & Hendricks, R. L. Infected cell protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8+ T cell response. J. Exp. Med. 187, 341–348 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-pd-1 immunotherapy. Cell 174, 1031–1032 (2018).
  Article CAS PubMed Google Scholar
• Ribas, A. et al. SD-101 in combination with pembrolizumab in advanced melanoma: results of a phase Ib, multicenter study. Cancer Discov. 8, 1250–1257 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Guiducci, C., Vicari, A. P., Sangaletti, S., Trinchieri, G. & Colombo, M. P. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65, 3437–3446 (2005).
  Article CAS PubMed Google Scholar
• Vicari, A. P. et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med. 196, 541–549 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Sagiv-Barfi, I. et al. Eradication of spontaneous malignancy by local immunotherapy. Sci. Transl. Med. 10, eaan4488 (2018).
  Article PubMed PubMed Central CAS Google Scholar
• Ishizuka, J. J. et al. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Nature 565, 43–48 (2018).
  Article PubMed CAS PubMed Central Google Scholar
• Wang, H. et al. cGAS is essential for the antitumor effect of immune checkpoint blockade. Proc. Natl Acad. Sci. USA 114, 1637–1642 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Morrison, A. H., Byrne, K. T. & Vonderheide, R. H. Immunotherapy and prevention of pancreatic cancer. Trends cancer 4, 418–428 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Byrne, K. T. & Vonderheide, R. H. CD40 stimulation obviates innate sensors and drives T cell immunity in cancer. Cell Rep. 15, 2719–2732 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Ma, D. Y. & Clark, E. A. The role of CD40 and CD154/CD40L in dendritic cells. Semin. Immunol. 21, 265–272 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Kloss, C. C. et al. Dominant-negative TGF-beta receptor enhances PSMA-targeted human car t cell proliferation and augments prostate cancer eradication. Mol. Ther. 26, 1855–1866 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Chang, Z. L. et al. Rewiring T-cell responses to soluble factors with chimeric antigen receptors. Nat. Chem. Biol. 14, 317–324 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Roybal, K. T. & Lim, W. A. Synthetic immunology: hacking immune cells to expand their therapeutic capabilities. Annu. Rev. Immunol. 35, 229–253 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Srivastava, S. et al. Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell 35, 489–503.e488 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Ljunggren, H. G. & Karre, K. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol. Today 11, 237–244 (1990).
  Article CAS PubMed Google Scholar
• Rezvani, K., Rouce, R., Liu, E. & Shpall, E. Engineering natural killer cells for cancer immunotherapy. Mol. Ther. 25, 1769–1781 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Andre, P. et al. Anti-NKG2A mAb Is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell 175, 1731–1743.e1713 (2018).
  Article CAS PubMed PubMed Central Google Scholar